Product Description: Loncastuximab tesirine is a human cluster of differentiation 19 (CD19)-directed antibody-drug conjugate (ADC). Once bound to CD19 on the cell membrane, loncastuximab tesirine is rapidly internalised and triggers cell death. Loncastuximab tesirin induces cell apoptosis, it can be used for the research of diffuse large B-cell lymphoma[1][2].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Nikoleta Sachini, et al. Combination of Loncastuximab Tesirine and Polatuzumab Vedotin Shows Increased Anti-Tumor Activity in Pre-Clinical Models of Non-Hodgkin Lymphoma. Blood. 2021./[2]Zammarchi F, et al. ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies. Blood. 2018 Mar 8;131(10):1094-1105.
CAS Number: 1879918-31-6
Molecular Weight: 147000 (average)
Compound Purity: 99.37
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: Antibody-Drug Conjugates (ADCs);Apoptosis
English
Deutsch
